Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

RAPT Therapeutics Announces Multiple Late-Breaking Presentations At The Upcoming American Association For Cancer Research Annual Meeting

Author: Benzinga Newsdesk | March 05, 2024 05:34pm

RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the acceptance of three late-breaking abstracts for poster presentation, including a poster presentation for tivumecirnon (FLX475), its lead oncology drug candidate, highlighting phase 2 clinical data in head and neck squamous cell carcinoma (HNSCC), at the American Association for Cancer Research (AACR) Annual Meeting which will take place April 5-10, 2024 in San Diego, CA.

 

Late-breaking poster presentation details:

Title:

 
Phase 2 Study of Oral CCR4 Antagonist FLX475 (tivumecirnon) Plus Pembrolizumab in Subjects with Head and Neck Squamous Cell Carcinoma (HNSCC) Previously Treated with Checkpoint Inhibitor
Abstract Number: 

 
CT226
Date & Time:

 
Tuesday, April 9, 2024; 9:00 a.m. – 12:30 p.m. PT
Session Title:

 
Phase II Clinical Trials 1
Location:

 
Poster Section 49

                        

 

Title:

 
A Combined mregDC and Treg Signature Associates with Antitumor Efficacy of CCR4 Antagonist Tivumecirnon FLX475
Abstract Number:

 
2485
Date & Time:

 
Monday, April 8, 2024; 9:00 a.m. - 12:30 p.m. PT
Session Title: 

 
Predictive Biomarkers 1
Location: 

 
Poster Section 43



 

Title: 

 
HPK1 inhibits CD8+ T cell effector gene expression following T cell activation
Abstract Number:

 
2654
Date & Time: 

 
Monday, April 8, 2024; 1:30 - 5:00 p.m. PT
Session Title: 

 
Immune Checkpoints and Inhibitory Molecules 2
Location: 

 
Poster Section 4

Late-breaking abstract titles are currently available on AACR's online itinerary planner, and late-breaking abstract text will be available on AACR's planner on April 5, 2024 at 12:00 p.m. PT. The planner can be accessed at: https://www.abstractsonline.com/pp8/#!/20272.

Posted In: RAPT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist